Background: Haloperidol is commonly prescribed to patients with alcohol-induced psychotic disorder (AIPD). Notably however, individuals differ extensively with regards to therapeutic response and adverse drug reactions (ADRs). Previous studies have shown that haloperidol biotransformation is mainly metabolized by CYP2D6. Objective: The objective of our study was to investigate the use of pharmacogenetic (CYP2D6*4 genetic polymorphism) and pharmacometabolomic biomarkers to predict haloperidol efficacy and safety rates. Material and Methods: The study enrolled 150 patients with AIPD. Therapy included haloperidol in a daily dose of 5 to 10 mg/day by injections for 5 days. Efficacy and safety of treatment were evaluated using the validated psychometric scales PANSS, UKU, and SAS. Results: No association of the urinary 6-НО-ТНВС/pinoline ratio values which could be evidence of the CYP2D6 activity level with both the efficacy and safety rates of haloperidol was demonstrated. However, a statistically significant association between haloperidol safety profile and CYP2D6*4 genetic polymorphism was demonstrated (P < .001). Conclusion: To predict haloperidol efficacy and safety rates, utilization of pharmacogenetic testing that defines CYP2D6*4 genetic polymorphism is found preferable over the use of the pharmacometabolomic marker in a clinical setting.
JordaanGPWarwickJMNelDGHewlettREmsleyR.Alcohol-induced psychotic disorder: brain perfusion and psychopathology–before and after anti-psychotic treatment. Metab Brain Dis. 2012;27(1):67-77. doi:10.1007/s11011-011-9273-7
2.
JordaanGPEmsleyR.Alcohol-induced psychotic disorder: A review. Metab Brain Dis. 2014;29(2):231-243. doi:10.1007/s11011-013-9457-4
3.
NarasimhaVLPatleyRShuklaLBenegalVKandasamyA.Phenomenology and course of alcoholic hallucinosis. J Dual Diagn. 2019;15(3):172-176. doi:10.1080/15504263.2019.1619008
4.
SurawiczFG.Alcoholic hallucinosis: a missed diagnosis: differential diagnosis and management. Can J Psychiatry. 1980; 25(1):57-63. doi:10.1177/070674378002500111
5.
de MillasWHaasenC. Treatment of alcohol hallucinosis with risperidone. Am J Addict. 2007;16(3):249-250. doi:10.1080/10550490701375269
6.
DoldMSamaraMTLiCTardyMLeuchtS.Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015;1:CD009831. doi:10.1002/14651858.CD009831.pub2
7.
SeemanPKapurS.Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A. 2000;97(14):7673-7675.
8.
OhnoYKunisawaNShimizuS.Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): management of Extrapyramidal Side Effects. Front Pharmacol. 2019;10:1045. doi:10.3389/fphar.2019.01045
KudoSIshizakiT.Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435-456. doi:10.2165/00003088-199937060-00001
11.
KozyraMIngelman-SundbergMLauschkeVM.Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017; 19(1):20-29. doi:10.1038/gim.2016.33
12.
SakuyamaKSasakiTUjiieS, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos. 2008; 36(12):2460-2467. doi:10.1124/dmd.108.023242
13.
MuroiYSaitoTTakahashiM, et al. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. Drug Metab Pharmacokinet. 2014;29(5):360-366. doi:10.2133/dmpk.dmpk-14-rg-014
14.
ZhouYIngelman-SundbergMLauschkeVM.Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688-700. doi:10.1002/cpt.690
CaudleKEDunnenbergerHMFreimuthRR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215-223. doi:10.1038/gim.2016.87
17.
TaylorCCrosbyIYipVMaguirePPirmohamedMTurnerRM.A review of the important role of CYP2D6 in Pharmacogenomics. Genes. 2020;11(11):1295. doi:10.3390/genes11111295
18.
JiangXLShenHWYuAM.Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos. 2009;37(3):443-446. doi:10.1124/dmd.108.025056
19.
KaySRFiszbeinAOplerLA.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261
20.
LingjærdeOAhlforsUGBechPDenckerSJElgenK.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;76:1-100. doi:10.1111/j.1600-0447.1987.tb10566.x
21.
SimpsonGMAngusJW.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19. doi:10.1111/j.1600-0447.1970.tb02066.x
22.
GaedigkASangkuhlKWhirl-CarrilloMKleinTLeederJS.Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69-76. doi:10.1038/gim.2016.80. Erratum in: Genet Med. 2016Nov;18(11):1167. PMID: 27388693; PMCID: PMC5292679.
